Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2

(2011) Sonia Servitja et al.   ANTI-CANCER DRUGS

Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)

(2011) David Cella et al.   BREAST CANCER RESEARCH AND TREATMENT

Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer

(2011) Patricia K. Corey-Lisle et al.   CANCER

Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer

(2011) Mark Barok et al.   CANCER LETTERS

Docetaxel combined with targeted therapies in metastatic breast cancer

(2011) Javier Cortes et al.   CANCER TREATMENT REVIEWS

Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial

(2011) Paul Hamberg et al.   Clinical Breast Cancer

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

(2010) Teemu T. Junttila et al.   BREAST CANCER RESEARCH AND TREATMENT

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

(2010) Beth Sherrill et al.   CURRENT MEDICAL RESEARCH AND OPINION

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

(2010) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis of Women With Metastatic Breast Cancer byHER2Status and Trastuzumab Treatment: An Institutional-Based Review

(2009) Shaheenah Dawood et al.   JOURNAL OF CLINICAL ONCOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer and Leukemia Group B Protocol 9840

(2008) Andrew D. Seidman et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Efficacy of Taxane-Trastuzumab Combination Regimens for HER-2-Positive Metastatic Breast Cancer

(2008) K. Bullock et al.   ONCOLOGIST

Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review

(2007) Julie Lemieux et al.   PSYCHO-ONCOLOGY